JAK/STAT Signaling

Cat.No. Product Name Information

B1493 AG-490 (Tyrphostin B42) AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

B1259 (3R,4S)-Tofacitinib Tasocitinib also known as CP690550 is an JAK kinase inhibitor. An IC50 estimated at 0.2 μM for PV patient progenitor cells.

B1031 (3S,4S)-Tofacitinib Tasocitinib also known as CP690550 is an JAK kinase inhibitor. An IC50 estimated at 0.2 μM for PV patient progenitor cells.

B1258 (3S,4R)-Tofacitinib Tasocitinib also known as CP690550 is an JAK kinase inhibitor. An IC50 estimated at 0.2 μM for PV patient progenitor cells.

B1130 GLPG0634 GLPGGLPG0634 is a selective inhibitor of JAK1 with IC50 value of 10nM .

B1105 AZD-9291 mesylate First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical benefit in patients with advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC).

B1104 AZD-9291 AZD-9291 is an irreversible inhibitor of mutant EGFR kinase with IC50 values of 15nM, 17nM and 480nM, respectively for L858R/T790M, ex19del and wild-type EGFR .

B1496 Icotinib Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).

B1103 Mutant EGFR inhibitor Mutant EGFR inhibitor is a selective and potent Mutated EGFR inhibitor(L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant).

B1020 AST-1306 TsOH AST-1306 is a selective, irreversible inhibitor of ErbB2 and EGFR with IC50 values of 0.5nM and 3nM, respectively .

Products for JAK/STAT Signaling